Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257738 · ClinicalTrials.gov registry record · Phase 1
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00257738 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 17 participants.
The verdict
NCT00257738, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a devastating illness, the treatment of which is associated with significant morbidity. This type of cancer affects 43,000 individuals each year with an estimated survival rate of 50%. A potential treatment alternative for this patient population is the use of peptide-based immunotherapy. This clinical tial will be using a vaccines comprised on the Trojan peptides MAGE-A3 and HPV 16 to treat patients with Squamous Cell Carcinoma of the Head and Neck who have recurrent, progressive or metastatic SCCHN.
Interventions
- BIOLOGICAL MAGE-A3
- BIOLOGICAL HPV-16 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257738
The ClinicalTrials.gov registry entry for NCT00257738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MAGE-A3 is the first listed.
NCT00257738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257738 about?
NCT00257738 is a clinical study titled "0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck". Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a devastating illness, the treatment of which is associated with significant morbidity. This type of cancer affects 43,000 individuals each year with an estimated survival rate of 50%. A potential treatment alternative for this patient populati...
What is the current status of trial NCT00257738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2005-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00257738?
The interventions under investigation include: MAGE-A3 (BIOLOGICAL), HPV-16 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00257738?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.